CA-DC-CONNECTED-CAR
7.8.2024 11:01:34 CEST | Business Wire | Press release
DC Connected Car GmbH, a trailblazer in AI-driven remote vehicle diagnostics, announces the closure of a €2.1M seed funding round. Led by Insurtech-fund VENPACE, this round includes contributions from Borusan Ventures, Atlas Ventures, Network.VC, and existing investors APX, Bloomhaus Ventures, and Business Angels. This investment accelerates DC Connected Car's mission to revolutionize the $500B automotive aftersales market with its virtual technician platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807187434/en/
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. (Graphic: Business Wire)
DC Connected Car's virtual technician platform addresses the shortage of skilled labor in the industry, and their remote diagnostics and advanced AI set new sector benchmarks. Unlike conventional diagnostics, AI-driven solutions deliver automated, intelligent insights into vehicle health and performance, providing real-time problem-solution recommendations. This approach minimizes the need for physical inspections/repairs, but also integrates into customers' lives by offering remote support. By combining AI with remote diagnostics, DC Connected Car redefines vehicle maintenance and customer convenience, solidifying its position as a standout player in the space, highlighted by its partnerships with Major OEMs.
"AI has the potential to revolutionize various automotive areas that Borusan operates in, such as aftersales, fleets, and used car business," said Timo Kilp, Head of Borusan Ventures. "We believe DC Connected Car's AI-driven digital technician holds significant promise to accelerate the diagnosis and repair of vehicle issues, further enhancing our customer service."
Not only disruptive in the automotive repair sector, DC Connected Car is driving innovations in the insurance industry too. Their partnership with Real Garant Versicherung AG marks a new era of digitalization, sustainable mobility, and future-orientated service design.
"With the cooperation with DC Connected Car GmbH, we expect to significantly contribute to environmentally friendly mobility solutions and to drive forward digitalization in the automotive sector by providing digital solutions for warranty and service products,” explains Suzana Janny, Head of Market Proposition at Real Garant Versicherung AG.
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. The company has seamlessly integrated and digitized expertise across various automotive departments, breaking down silos and enhancing efficiency.
About DC Connected Car GmbH
Founded in 2020 in Leibi, Germany, DC Connected Car offers an all-in-one solution that represents the virtual vehicle technician of the future. This platform addresses the complexities of modern vehicle generations and labor shortage by enabling automated and intelligent diagnostic and repair processes.
"What excites us most about DC Connected Car is the wide range of possible applications for their virtual assistant in the mobility ecosystem. Insurers especially have a high interest in elevating their customer experience by digitizing roadside assistance services. In addition, the team has already impressively demonstrated that it has been able to win well-known B2B customers and OEMs as partners," said Tizian Hoppen of VENPACE.
The team behind DC Connected Car includes experts with deep industry knowledge and experience. Dennis Christ, an expert in automotive technology and a certified appraiser, provides precise and reliable diagnostic procedures. Ralf Schollenberger leverages his extensive network and expertise in insurance and the aftermarket to forge strategic partnerships. Willian Servigna, specializing in AI and software development, ensures that solutions remain at the forefront of technology.
About VENPACE - VENPACE is a leading investor from the insurance space, guiding startups with unique expertise to sustainably scale innovative solutions. Together with partners throughout the DACH region, they tackle the insurance industry’s challenges head-on, developing and establishing innovative business models.
About BORUSAN Ventures - Borusan Ventures is the corporate venture capital arm of Borusan Group, a prominent industrial group in the U.S., Europe and CIS region. Headquartered in Silicon Valley, Borusan Ventures invests in early-stage startups in the U.S. and Europe, focusing on mobility, supply chain/logistics, energy/climate, enterprise, and industrial sectors.
About ATLAS Ventures - Atlas Ventures is a UK-based industrial tech fund focussed on investing in seed and late seed stage opportunities in Developed European markets, with a primary focus on innovative B2B solutions targeting industrial manufacturing, energy and climate, mobility, supply chain and logistics sectors.
For more information, visit https://www.dc-connected.de/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807187434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom